Drug Shortage Report for ACYCLOVIR SODIUM INJECTION
Report ID | 111367 |
Drug Identification Number | 02236926 |
Brand name | ACYCLOVIR SODIUM INJECTION |
Common or Proper name | Acyclovir Sodium Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | ACYCLOVIR |
Strength(s) | 50MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | Vial 20 mL |
ATC code | J05AB |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Shortage of an active ingredient. |
Anticipated start date | |
Actual start date | 2020-04-01 |
Estimated end date | Unknown |
Actual end date | 2020-08-14 |
Shortage status | Resolved |
Updated date | 2020-08-17 |
Company comments | Our stock of Acyclovir Sodium Injection 50 mg/mL, 10 mL and 20 mL vials is expected to deplete by August 14, 2020. The product will remain on reduced allocation until stock is depleted. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2020-08-17 | French | Compare |
v3 | 2020-08-17 | English | Compare |
v2 | 2020-04-07 | French | Compare |
v1 | 2020-04-07 | English | Compare |
Showing 1 to 4 of 4